Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second ...

HealthDay News — For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes, according to a study ...

Novo Nordisk (NVO) announced Friday that the U.S. Food and Drug Administration (FDA) accepted its marketing application for ...

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of researchers has now discovered it can also do wonders for people who have ...

While there is not currently a shortage of Ozempic, previous difficulties in supplying this medication have led to some pharmacies offering compounded semaglutide. The Food and Drug Administration ...

Novo offers semaglutide ... drugs on the market, Lilly said. The study measured weight loss as a secondary goal. The drug reduced weight by an average of 16 pounds, or 7.9%, at the highest dose ...

Analyst calls orforglipron a potential “Ozempic in a pill ... dosage in the SUSTAIN-1 trial. In addition, orforglipron delivered A1C reductions of up to 1.6%, aligning with injectable ...

Forbes contributors publish independent expert analyses and insights.

The ACHIEVE-1 trial results revealed an average A1C reduction of 1.3-1.6% across different doses, with the highest dose leading to ... injectable treatments like semaglutide and tirzepatide ...